Cargando…

Inorganic Nanocarriers Overcoming Multidrug Resistance for Cancer Theranostics

Cancer multidrug resistance (MDR) could lead to therapeutic failure of chemotherapy and radiotherapy, and has become one of the main obstacles to successful cancer treatment. Some advanced drug delivery platforms, such as inorganic nanocarriers, demonstrate a high potential for cancer theranostic to...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Gan, Mi, Peng, Chu, Chengchao, Zhang, Jun, Liu, Gang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5102675/
https://www.ncbi.nlm.nih.gov/pubmed/27980988
http://dx.doi.org/10.1002/advs.201600134
_version_ 1782466467143352320
author Lin, Gan
Mi, Peng
Chu, Chengchao
Zhang, Jun
Liu, Gang
author_facet Lin, Gan
Mi, Peng
Chu, Chengchao
Zhang, Jun
Liu, Gang
author_sort Lin, Gan
collection PubMed
description Cancer multidrug resistance (MDR) could lead to therapeutic failure of chemotherapy and radiotherapy, and has become one of the main obstacles to successful cancer treatment. Some advanced drug delivery platforms, such as inorganic nanocarriers, demonstrate a high potential for cancer theranostic to overcome the cancer‐specific limitation of conventional low‐molecular‐weight anticancer agents and imaging probes. Specifically, it could achieve synergetic therapeutic effects, demonstrating stronger killing effects to MDR cancer cells by combining the inorganic nanocarriers with other treatment manners, such as RNA interference and thermal therapy. Moreover, the inorganic nanocarriers could provide imaging functions to help monitor treatment responses, e.g., drug resistance and therapeutic effects, as well as analyze the mechanism of MDR by molecular imaging modalities. In this review, the mechanisms involved in cancer MDR and recent advances of applying inorganic nanocarriers for MDR cancer imaging and therapy are summarized. The inorganic nanocarriers may circumvent cancer MDR for effective therapy and provide a way to track the therapeutic processes for real‐time molecular imaging, demonstrating high performance in studying the interaction of nanocarriers and MDR cancer cells/tissues in laboratory study and further shedding light on elaborate design of nanocarriers that could overcome MDR for clinical translation.
format Online
Article
Text
id pubmed-5102675
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-51026752016-11-16 Inorganic Nanocarriers Overcoming Multidrug Resistance for Cancer Theranostics Lin, Gan Mi, Peng Chu, Chengchao Zhang, Jun Liu, Gang Adv Sci (Weinh) Reviews Cancer multidrug resistance (MDR) could lead to therapeutic failure of chemotherapy and radiotherapy, and has become one of the main obstacles to successful cancer treatment. Some advanced drug delivery platforms, such as inorganic nanocarriers, demonstrate a high potential for cancer theranostic to overcome the cancer‐specific limitation of conventional low‐molecular‐weight anticancer agents and imaging probes. Specifically, it could achieve synergetic therapeutic effects, demonstrating stronger killing effects to MDR cancer cells by combining the inorganic nanocarriers with other treatment manners, such as RNA interference and thermal therapy. Moreover, the inorganic nanocarriers could provide imaging functions to help monitor treatment responses, e.g., drug resistance and therapeutic effects, as well as analyze the mechanism of MDR by molecular imaging modalities. In this review, the mechanisms involved in cancer MDR and recent advances of applying inorganic nanocarriers for MDR cancer imaging and therapy are summarized. The inorganic nanocarriers may circumvent cancer MDR for effective therapy and provide a way to track the therapeutic processes for real‐time molecular imaging, demonstrating high performance in studying the interaction of nanocarriers and MDR cancer cells/tissues in laboratory study and further shedding light on elaborate design of nanocarriers that could overcome MDR for clinical translation. John Wiley and Sons Inc. 2016-05-30 /pmc/articles/PMC5102675/ /pubmed/27980988 http://dx.doi.org/10.1002/advs.201600134 Text en © 2016 The Authors. Published by WILEY‐VCH Verlag GmbH & Co. KGaA, Weinheim This is an open access article under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Reviews
Lin, Gan
Mi, Peng
Chu, Chengchao
Zhang, Jun
Liu, Gang
Inorganic Nanocarriers Overcoming Multidrug Resistance for Cancer Theranostics
title Inorganic Nanocarriers Overcoming Multidrug Resistance for Cancer Theranostics
title_full Inorganic Nanocarriers Overcoming Multidrug Resistance for Cancer Theranostics
title_fullStr Inorganic Nanocarriers Overcoming Multidrug Resistance for Cancer Theranostics
title_full_unstemmed Inorganic Nanocarriers Overcoming Multidrug Resistance for Cancer Theranostics
title_short Inorganic Nanocarriers Overcoming Multidrug Resistance for Cancer Theranostics
title_sort inorganic nanocarriers overcoming multidrug resistance for cancer theranostics
topic Reviews
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5102675/
https://www.ncbi.nlm.nih.gov/pubmed/27980988
http://dx.doi.org/10.1002/advs.201600134
work_keys_str_mv AT lingan inorganicnanocarriersovercomingmultidrugresistanceforcancertheranostics
AT mipeng inorganicnanocarriersovercomingmultidrugresistanceforcancertheranostics
AT chuchengchao inorganicnanocarriersovercomingmultidrugresistanceforcancertheranostics
AT zhangjun inorganicnanocarriersovercomingmultidrugresistanceforcancertheranostics
AT liugang inorganicnanocarriersovercomingmultidrugresistanceforcancertheranostics